Literature DB >> 8665496

Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells.

W Hamel1, L Magnelli, V P Chiarugi, M A Israel.   

Abstract

An emerging strategy for cancer gene therapy involves the transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells, rendering them susceptible to the cytotoxic effects of ganciclovir. The observation that HSV-tk-expressing cells can also induce cell death in neighboring cells, which do not express HSV-tk, has been called the bystander effect. Gap junction-mediated transfer of cytotoxic molecules to bystander cells may be an important mechanism of bystander cell death, although others have suggested a role for phagocytosis. In this study, we evaluated the mode of cell death in bystander cells. We detected apoptosis in bystander cells and found that bystander cell death could be inhibited by BCL2 expression. We determined that ganciclovir incubations for 10 h were sufficient to induce cell death in most bystander cells cocultured with HSV-tk-expressing cells. During this period, no phagocytosis was detected, although it was obvious at later stages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665496

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus.

Authors:  Brenda F Canine; Yuhua Wang; Wenyun Ouyang; Arash Hatefi
Journal:  J Control Release       Date:  2010-12-28       Impact factor: 9.776

2.  In vivo imaging of intraprostatic-specific gene transcription by PET.

Authors:  Frédéric Pouliot; Breanne D W Karanikolas; Mai Johnson; Makoto Sato; Saul J Priceman; David Stout; Joanne Sohn; Nagichettiar Satyamurthy; Jean B deKernion; Lily Wu
Journal:  J Nucl Med       Date:  2011-04-15       Impact factor: 10.057

3.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

4.  The design and optimization of RNA trans-splicing molecules for skin cancer therapy.

Authors:  Christina Gruber; Ulrich Koller; Eva M Murauer; Stefan Hainzl; Clemens Hüttner; Thomas Kocher; Andrew P South; Helmut Hintner; Johann W Bauer
Journal:  Mol Oncol       Date:  2013-08-19       Impact factor: 6.603

Review 5.  The promise and reality of cancer gene therapy.

Authors:  S J Hall; S H Chen; S L Woo
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

6.  Neural stem cell-based gene therapy for brain tumors.

Authors:  Seung U Kim
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

7.  Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene.

Authors:  T Goto; T Nishi; T Tamura; S B Dev; H Takeshima; M Kochi; K Yoshizato; J Kuratsu; T Sakata; G A Hofmann; Y Ushio
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

8.  Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors.

Authors:  Panagiotis Mastorakos; Clark Zhang; Eric Song; Young Eun Kim; Hee Won Park; Sneha Berry; Won Kyu Choi; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2017-07-08       Impact factor: 9.776

9.  Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.

Authors:  Donna N Douglas; Toshiyasu Kawahara; Banu Sis; David Bond; Karl P Fischer; D Lorne J Tyrrell; Jamie T Lewis; Norman M Kneteman
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

10.  Bystander-mediated regression of murine neuroblastoma via retroviral transfer of the HSV-TK gene.

Authors:  Hyun-Sang Cho; Hye-Ran Lee; Moon Kyu Kim
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.